ATLANTA, July 31, 2013 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced it received recognitions in several categories at the 2013 American Business Awards, also called "The Stevies," held last month at the Fairmont Hotel in Chicago.
Avion submitted entries for business excellence and performance in relation to its successful launch of Prenate® Mini prenatal vitamin in 2012. As a result, the company was recognized for outstanding accomplishments across several categories based on receiving high average scores during more than five weeks of judging.
The Stevie Awards were created in 2002 to honor and generate public recognition of the achievements and positive contributions of organizations and business people worldwide. Judged each year by more than 200 executives nationwide, the Stevie Awards were designed to raise the profile of exemplary organizations and individuals among the press, the business community, and the general public for their achievements in work life.
Avion proudly announces the following categories in which it received recognition:
"Our team at Avion is focused on flawless launch planning and execution. We work diligently to strategically and tactically develop new products that will benefit both mom and baby and help support our very important Ob/Gyn partner community," stated Mike Sullivan, Vice President, Sales and Marketing, for Avion Pharmaceuticals.
"Avion Pharmaceuticals is thrilled to be honored with these awards from a very respected and established organization. To be recognized with a 'Stevie' sets the bar very high and encourages us to continue our focus on innovation and utility in all upcoming launch efforts," added Mark Pugh, CEO.
About Avion Pharmaceuticals, LLC.
Avion Pharmaceuticals, LLC is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women's Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188 or visit www.avionrx.com.
|SOURCE Avion Pharmaceuticals, LLC|
Copyright©2012 PR Newswire.
All rights reserved